Literature DB >> 8922147

Nasal polyps treatment: medical management.

N Mygind1, T Lildholdt.   

Abstract

The objectives of medical management of nasal polyposis are 1) to eliminate nasal polyps and rhinitis symptoms, 2) to reestablish nasal breathing and olfaction, and 3) to prevent recurrence of nasal polyps. Although antibiotics are used for infectious complications of nasal polyposis, only glucocorticosteroids (steroids) have a proven effect on the symptoms and signs of nasal polyps. Topically applied steroids is the therapeutic modality that has been best studied in controlled trials. It reduces rhinitis symptoms, improves nasal breathing, reduces the size of polyps and the recurrence rate, but it has a negligible effect on the sense of smell and on any sinus pathology. Topical steroids can, as long-term therapy, be used alone in mild cases, or combined with systemic steroids/surgery in severe cases. Systemic steroids, which are less well studied, have an effect on all types of symptoms and pathology, including the sense of smell. This type of treatment, which can serve a "medical polypectomy," is only used for short-term improvement due to the risk of adverse effects. Individualized management of nasal polyposis may use long-term topical steroids, short-term systemic steroids, as well as surgery, in various combinations. Exactly how these therapies, which differ in their control of various symptoms, are optimally combined is not yet well established.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8922147     DOI: 10.2500/108854196778662228

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  14 in total

1.  Topical beclomethasone in the therapy of smelling disorders-a new application technique.

Authors:  Franca Fleiner; Onder Goktas
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-01-12

2.  Cost effectiveness of nasal budesonide versus surgical treatment for nasal polyps.

Authors:  Fredrik Berggren; Leif Johansson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Availability of preoperative systemic steroids on endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis.

Authors:  Seok Jin Hong; Jong Kyu Lee; Hyun Sub Lee; Jung Yup Lee; Jung Soo Pyo; Kyung Chul Lee
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

4.  Comparison of the effect of endoscopic sinus surgery versus medical therapy on olfaction in nasal polyposis.

Authors:  Mohammad Hossein Baradaranfar; Zeynab Sadat Ahmadi; Mohammad Hossein Dadgarnia; Mohammad Hossein Bemanian; Saeid Atighechi; Ghasem Karimi; Abolhasan Halvani; Nasim Behniafard; Amin Baradaranfar; Tohid Emami Meybodi
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-23       Impact factor: 2.503

Review 5.  Comparison of medical and surgical treatment of nasal polyposis.

Authors:  Glenis K Scadding
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

Review 6.  [Olfactory dysfunctions. Epidemiology and therapy in Germany, Austria and Switzerland].

Authors:  M Damm; A Temmel; A Welge-Lüssen; H E Eckel; M-P Kreft; J P Klussmann; H Gudziol; K-B Hüttenbrink; T Hummel
Journal:  HNO       Date:  2004-02       Impact factor: 1.284

7.  Effect of laser treatment on olfactory dysfunction.

Authors:  Onder Göktas; Larissa Lau; Franca Fleiner
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-12-20

Review 8.  Nonallergic rhinitis with eosinophilia syndrome.

Authors:  Anne K Ellis; Paul K Keith
Journal:  Curr Allergy Asthma Rep       Date:  2006-05       Impact factor: 4.919

Review 9.  Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis.

Authors:  Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26

Review 10.  Short-course oral steroids alone for chronic rhinosinusitis.

Authors:  Karen Head; Lee Yee Chong; Claire Hopkins; Carl Philpott; Martin J Burton; Anne G M Schilder
Journal:  Cochrane Database Syst Rev       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.